# A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia

> **NCT07218900** · PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 76 (estimated)

## Conditions studied

- Dyslipidaemia

## Interventions

- **DRUG:** Placebo
- **DRUG:** AZD0780
- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT07218900
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-13
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07218900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07218900, "A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07218900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*